Antazoline

Antazoline Overview

Antazoline (chemical formula C17H19N3) is a first-generation, imidazoline-substituted ethylenediamine H1-receptor antagonist. Chemically, it belongs to the class of organic compounds known as phenylbenzamines within the benzenoids superclass. Structurally, it consists of an N-benzyl-N-phenylamino core attached to a 4,5-dihydro-1H-imidazol-2-ylmethyl moiety, combining an aromatic amine with a functional imidazoline ring.

In clinical immunology, ophthalmology, and rhinology, Antazoline functions as a topical antihistamine, antipruritic, and mild anticholinergic agent (ATC codes R01AC04 for nasal anti-allergics and R06AX05 for systemic antihistamines). Formulated as Antazoline phosphate, Antazoline hydrochloride, or Antazoline sulfate, it is most widely utilized in combination ophthalmic eye drops alongside alpha-adrenergic vasoconstrictors such as naphazoline or tetrahydrozoline (most prominently under the brand name Vasocon-A). It is indicated for the temporary relief of ocular redness, itching, lacrimation, and chemosis associated with seasonal and perennial allergic conjunctivitis, as well as symptomatic relief of allergic nasal congestion.

What Is Antazoline and How Does It Work?

Antazoline acts primarily through competitive antagonism of ocular and mucosal histamine H1 receptors.

Its primary chemical, physiological, and cellular mechanisms include:

• Competitive Histamine H1 Receptor Blockade: Antazoline binds reversibly and competitively to histamine H1 receptors located on conjunctival vascular endothelial cells, ocular sensory nerve endings, and nasal mucosal membranes. By preventing endogenous histamine from binding, it halts histamine-mediated vasodilation, microvascular leakage, hyper-permeability, and local sensory nerve stimulation.
• Ocular Symptom Suppression: In allergic conjunctivitis, blockade of H1 receptors on conjunctival mast cells and blood vessels rapidly reduces itching (pruritus), chemosis (conjunctival swelling), hyperlacrimation (tearing), and ocular hyperemia (redness).
• Synergistic Action with Alpha-Agonists: When co-formulated with imidazoline vasoconstrictors (such as naphazoline or tetrahydrozoline), Antazoline provides targeted H1 blockade while the alpha-adrenergic agonist induces direct conjunctival arteriolar constriction. This dual-action mechanism provides rapid relief from ocular redness and itching.
• Mild Anticholinergic & Local Anesthetic Activity: Antazoline exhibits weak-to-moderate anticholinergic activity and mild membrane-stabilizing (local anesthetic) properties, contributing to reduced local ocular irritation and tissue secretion.

Is Antazoline FDA Approved?

Antazoline was historically approved by the US FDA as a prescription ophthalmic solution (Vasocon-A, formulated as antazoline phosphate combined with naphazoline HCl) in April 1990. However, commercial distribution of brand-name Vasocon-A has been discontinued in North America, with its final regulatory discontinuation finalized in July 2010 due to corporate business strategy shifts rather than safety issues, as the ocular market transitioned heavily toward advanced, highly selective dual-action antihistamine/mast-cell stabilizers (such as olopatadine or ketotifen).

What Is Antazoline Used For?

• Temporary relief of ocular itching, burning, redness, and tearing caused by allergic conjunctivitis (due to pollen, ragweed, grass, animal dander, or environmental allergens).
• Symptomatic relief of ocular hyperemia and chemosis when combined with naphazoline or tetrahydrozoline.
• Historical treatment of allergic rhinitis and nasal congestion (nasal formulation).

Before Using Antazoline: Contraindications & Precautions

Evaluate for documented severe hypersensitivity to Antazoline, imidazoline derivatives, or formulation excipients (such as benzalkonium chloride) before prescribing. Antazoline combination eye drops are strictly contraindicated in patients with narrow-angle (closed-angle) glaucoma due to the risk of precipitating an acute angle-closure crisis via pupillary dilation. Contraindicated in children under 6 years of age unless directed by an ophthalmologist, and in patients currently taking monoamine oxidase inhibitors (MAOIs) due to systemic hypertensive risks associated with the co-formulated alpha-adrenergic vasoconstrictor (e.g., naphazoline). Systemic absorption following topical application is low, but use during pregnancy and lactation requires cautious clinical risk-benefit evaluation.

Who Should Not Use Antazoline Eye Drops?

• Individuals with a documented severe hypersensitivity to Antazoline, imidazoline derivatives, or ophthalmic formulation components (e.g., benzalkonium chloride preservative).
• Patients with narrow-angle (closed-angle) glaucoma, because sympathomimetic combination agents (e.g., naphazoline) or anticholinergic dilation can precipitate acute angle-closure glaucoma.
• Children under 6 years of age, unless evaluated and directed by a pediatric ophthalmologist.
• Patients taking monoamine oxidase inhibitors (MAOIs) concurrently, due to risks of systemic hypertensive crises from the combined alpha-adrenergic vasoconstrictor component.

Antazoline, Pregnancy & Lactation

Systemic absorption following topical ocular instillation of 1 to 2 drops is minimal. However, robust controlled human reproductive trials are limited. Antazoline combination eye drops should be used during pregnancy only if clearly needed. Exercise caution when administering to nursing mothers.

Tell Your Doctor Before Using Antazoline

Inform your eye care specialist or physician if you have a history of glaucoma, high blood pressure, heart disease, thyroid disorders, diabetes, or if you wear soft contact lenses.

Antazoline Dosage & Administration

Standard adult and pediatric (ages 6 and older) dosing for combination ophthalmic solutions (e.g., Vasocon-A) is 1 to 2 drops instilled into the conjunctival sac of the affected eye(s) up to 4 times daily as needed. Continuous therapy must be strictly limited to a maximum of 3 to 5 consecutive days to prevent rebound conjunctival hyperemia (conjunctivitis medicamentosa).

Standard Ophthalmic Dosing Guidelines

• Adults and Children 6 Years of Age and Older (Combination Eye Drops, e.g., Vasocon-A): Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) up to 4 times daily as needed.
• Duration Limit: Do NOT use continuously for longer than 3 to 5 consecutive days without consulting an eye care professional, to prevent rebound conjunctival hyperemia (redness) from the vasoconstrictor component.

How Antazoline Is Administered

1. Wash hands thoroughly before applying eye drops.
2. Remove contact lenses prior to instillation. Wait at least 15 minutes before reinserting soft contact lenses, as preservatives (like benzalkonium chloride) can be absorbed by soft lenses.
3. Tilt head backward, pull down the lower eyelid to create a small pocket, and look upward.
4. Instill 1 drop into the lower eyelid pocket without touching the dropper tip to the eye, eyelid, hands, or any surface.
5. Close eye gently and perform nasolacrimal occlusion (apply gentle pressure with a finger to the inner corner of the eye next to the nose) for 1 to 2 minutes to minimize systemic drug absorption.

Antazoline Clinical Efficacy & Safety Profile

Clinical ophthalmology trials establish that combination eye drops containing Antazoline 0.5% and Naphazoline 0.05% provide significantly greater and faster relief from ocular itching and redness than either agent used alone. Comparative clinical studies in environmental exposure chambers demonstrate that Antazoline/naphazoline drops achieve rapid onset of antipruritic action within 10 to 15 minutes, with therapeutic efficacy lasting 4 to 6 hours. However, prolonged overuse beyond 5 days is limited by the risk of rebound hyperemic congestion (conjunctivitis medicamentosa) caused by alpha-adrenergic receptor desensitization.

Antazoline Side Effects & Safety Profile

Antazoline acts via competitive antagonism at ocular and mucosal histamine H1 receptors, complemented by mild anticholinergic and local anesthetic activity. Common side effects include transient ocular stinging, burning, mild mydriasis, photophobia, and brief blurred vision upon instillation. Serious adverse events include rebound conjunctival hyperemia from overuse beyond 3 to 5 days, acute angle-closure glaucoma in susceptible individuals, ocular contact blepharoconjunctivitis, and systemic sympathomimetic effects (tachycardia, hypertension, headache) from nasolacrimal absorption. Commercial distribution of brand-name Vasocon-A was voluntarily discontinued in the US in July 2010 as ophthalmic practice shifted toward non-sedating dual-action mast cell stabilizers/antihistamines (e.g., olopatadine, ketotifen).

Common Side Effects

• Localized ocular stinging, burning, or mild transient discomfort upon instillation.
• Transient mydriasis (pupil dilation) and mild sensitivity to bright light.
• Temporary blurred vision immediately following drop placement.

Serious Adverse Events

• Rebound Conjunctival Hyperemia: Severe, persistent eye redness caused by overuse beyond 3 to 5 consecutive days.
• Acute Angle-Closure Glaucoma Crisis: Sudden severe eye pain, blurred vision, halo vision, and headache in individuals with anatomically narrow anterior chamber angles.
• Systemic Sympathomimetic & Anticholinergic Effects: Tachycardia, elevated blood pressure, headache, nervousness, dizziness, and dry mouth (occurring primarily from systemic absorption following excessive instillation).
• Ocular Hypersensitivity: Severe eyelid swelling, contact blepharoconjunctivitis, and intense itching.

Managing Side Effects

If severe eye pain, vision changes, or worsening redness occurs, discontinue use immediately and seek urgent ophthalmic evaluation. Perform nasolacrimal occlusion during instillation to prevent systemic side effects.

Antazoline Drug Interactions & What to Avoid

Co-administration with MAOIs or use within 14 days of stopping an MAOI is strictly contraindicated due to the risk of severe hypertensive crises driven by the co-formulated alpha-agonist component. Synergistic pressor responses occur when combined with tricyclic antidepressants. Allow at least 5 to 10 minutes between instilling Antazoline and other topical ophthalmic solutions. Avoid wearing soft contact lenses during active instillation sessions.

Drug-Drug Interactions

• Monoamine Oxidase Inhibitors (MAOIs, e.g., Phenelzine, Tranylcypromine, Selegiline): Co-administration with MAOIs or use within 14 days of stopping an MAOI can trigger severe hypertensive crises due to enhanced sympathomimetic responsiveness from co-formulated naphazoline.
• Tricyclic Antidepressants (TCAs): Potentiates the vasopressor response of alpha-adrenergic combination components.
• Other Ophthalmic Medications: Allow at least 5 to 10 minutes between instilling Antazoline eye drops and other topical ocular medications.

Physical & Lifestyle Hazards

Remove contact lenses prior to use. Avoid driving or operating machinery if temporary blurred vision or pupil dilation occurs.

Antazoline Overdose, Emergency & Clearance

Topical ophthalmic instillation provides targeted ocular drug delivery, with systemic absorption occurring primarily via nasolacrimal drainage. Systemically absorbed Antazoline undergoes hepatic metabolism and renal clearance. Accidental oral ingestion—especially in pediatric patients—presents severe toxicological hazards driven by the co-formulated imidazoline vasoconstrictor, causing central nervous system depression, hypothermia, bradycardia, hypotension, respiratory depression, and coma. Management requires emergency poison control intervention, supportive ICU monitoring, and cardiovascular management. Store solutions at 15°C to 25°C, protected from excessive heat, freezing, and direct light.

Elimination Kinetics & Overdose

Topical ophthalmic application delivers localized active drug directly to conjunctival tissues. Systemic absorption occurs via nasolacrimal drainage through the nasal mucosa into the bloodstream. Systemically absorbed Antazoline undergoes hepatic metabolism and renal excretion. Accidental oral ingestion of bottle contents (especially by young children) presents severe toxicological risks driven by the alpha-2 adrenergic component (naphazoline/tetrahydrozoline), causing central nervous system depression, severe hypothermia, bradycardia, hypotension, respiratory depression, and coma. Emergency management of accidental oral ingestion requires immediate poison control contact, intensive ICU monitoring, airway protection, and supportive cardiovascular care.

Storage & Handling

Store ophthalmic solutions at controlled room temperature between 15°C and 25°C (59°F to 77°F). Protect from excessive heat, freezing, and direct light. Keep container tightly closed when not in use. Discard unused solution if it changes color or becomes cloudy. Keep strictly out of reach of children.

Antazoline Patient Management & Safety Protocols

Enforce the strict 3- to 5-day duration cap to prevent rebound conjunctival redness. Instruct patients on proper nasolacrimal occlusion techniques and ensure contact lenses are removed prior to instillation and reinserted no earlier than 15 minutes post-dose.

Clinical Monitoring Checklist

• Verify that the patient does not have narrow-angle glaucoma or take MAOIs.
• Instruct patient on proper nasolacrimal occlusion techniques during eye drop instillation.
• Enforce the 3- to 5-day maximum duration limit to prevent rebound redness.
• Confirm that soft contact lenses are removed before instillation and reinserted after 15 minutes.

Key Do’s and Don’ts

• Do wash hands and perform nasolacrimal occlusion after instilling drops.
• Do wait at least 5 to 10 minutes before applying other eye drops.
• Do cap the usage duration at a maximum of 3 to 5 consecutive days.
• Do not touch the dropper tip to any surface or to the eye itself.
• Do not use while wearing soft contact lenses.
• Do not use if the eye solution changes color or becomes cloudy.
• Do not give to children under 6 years old without specialist supervision.

Frequently Asked Questions

References

• DrugBank Database – Antazoline Profile (DB08799)
• Classyfire Database – Phenylbenzamines / Imidazolines Chemical Taxonomy Profile
• American Academy of Ophthalmology (AAO) – Preferred Practice Pattern: Allergic Conjunctivitis Management
• Journal of Ocular Pharmacology and Therapeutics – Comparative Efficacy of Topical Ocular Antihistamines

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.